An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco

Abdul R Shihabi,1 Essam M Moussa,2 Hania Sobierajska,3 Birgit Schmidt4 1Al Ain Centre, Dubai, United Arab Emirates; 2New Jeddah Hospital, Jeddah, Saudi Arabia; 3Etihad Airways Medical Centre, Abu Dhabi, United Arab Emirates; 4Bayer Schering Pharma AG, Leverkusen, Germany Background: The prevalence o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shihabi AR, Moussa EM, Sobierajska H, Schmidt B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/1549223104274878bc35fe84a2e17f12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1549223104274878bc35fe84a2e17f12
record_format	dspace
spelling	oai:doaj.org-article:1549223104274878bc35fe84a2e17f122021-12-02T06:59:38ZAn observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco1178-7007https://doaj.org/article/1549223104274878bc35fe84a2e17f122013-04-01T00:00:00Zhttp://www.dovepress.com/an-observational-study-of-acarbose-treatment-in-patients-with-type-2-d-a12695https://doaj.org/toc/1178-7007Abdul R Shihabi,1 Essam M Moussa,2 Hania Sobierajska,3 Birgit Schmidt4 1Al Ain Centre, Dubai, United Arab Emirates; 2New Jeddah Hospital, Jeddah, Saudi Arabia; 3Etihad Airways Medical Centre, Abu Dhabi, United Arab Emirates; 4Bayer Schering Pharma AG, Leverkusen, Germany Background: The prevalence of type 2 diabetes is increasing dramatically in the Middle East and North Africa region. However, there are few trials that have determined the effect of antidiabetic treatment in an observational setting in these countries. Methods: This was a noninterventional study performed in Morocco in 2006–2007 and in the Middle East in 2005–2006 to observe the efficacy and safety of acarbose in patients with pretreated or untreated type 2 diabetes. Glycemic parameters (fasting blood glucose, one-hour postprandial blood glucose, and HbA1c) were recorded within a 3-month period. The observation period included an initial visit at the start of acarbose therapy and up to three follow-ups. Results: Acarbose was effective in reducing glycemic parameters in patients from Morocco (n = 1082) and the Middle East (n = 1737). The mean one-hour postprandial blood glucose decreased by 35.5% to 165.4 ± 47.9 mg/dL in the Middle East and by 35.5% to 179.0 ± 49.9 mg/dL in Morocco. Mean fasting blood glucose decreased by 30.8% to 126.6 ± 34.2 mg/dL (Middle East) and by 34.5% to 150.6 ± 47.1 mg/dL (Morocco). The absolute reduction in HbA1c was 1.3% in the Middle East (final value 7.4%) and 1.0% in Morocco (final value 7.5%). Overall, 107 patients (Middle East) and 26 patients (Morocco) experienced minor drug-related adverse events, which were mainly gastrointestinal. The tolerability of acarbose was rated as very good/good by 80.8% in the Middle East and by 68.6% in Morocco. Conclusion: This study illustrates the efficacy and safety of acarbose in the treatment of type 2 diabetic patients in an observational setting. Keywords: type 2 diabetes, acarbose, Glucobay®, Glucor®, observational, noninterventionalShihabi ARMoussa EMSobierajska HSchmidt BDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 141-150 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Shihabi AR Moussa EM Sobierajska H Schmidt B An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco
description	Abdul R Shihabi,1 Essam M Moussa,2 Hania Sobierajska,3 Birgit Schmidt4 1Al Ain Centre, Dubai, United Arab Emirates; 2New Jeddah Hospital, Jeddah, Saudi Arabia; 3Etihad Airways Medical Centre, Abu Dhabi, United Arab Emirates; 4Bayer Schering Pharma AG, Leverkusen, Germany Background: The prevalence of type 2 diabetes is increasing dramatically in the Middle East and North Africa region. However, there are few trials that have determined the effect of antidiabetic treatment in an observational setting in these countries. Methods: This was a noninterventional study performed in Morocco in 2006–2007 and in the Middle East in 2005–2006 to observe the efficacy and safety of acarbose in patients with pretreated or untreated type 2 diabetes. Glycemic parameters (fasting blood glucose, one-hour postprandial blood glucose, and HbA1c) were recorded within a 3-month period. The observation period included an initial visit at the start of acarbose therapy and up to three follow-ups. Results: Acarbose was effective in reducing glycemic parameters in patients from Morocco (n = 1082) and the Middle East (n = 1737). The mean one-hour postprandial blood glucose decreased by 35.5% to 165.4 ± 47.9 mg/dL in the Middle East and by 35.5% to 179.0 ± 49.9 mg/dL in Morocco. Mean fasting blood glucose decreased by 30.8% to 126.6 ± 34.2 mg/dL (Middle East) and by 34.5% to 150.6 ± 47.1 mg/dL (Morocco). The absolute reduction in HbA1c was 1.3% in the Middle East (final value 7.4%) and 1.0% in Morocco (final value 7.5%). Overall, 107 patients (Middle East) and 26 patients (Morocco) experienced minor drug-related adverse events, which were mainly gastrointestinal. The tolerability of acarbose was rated as very good/good by 80.8% in the Middle East and by 68.6% in Morocco. Conclusion: This study illustrates the efficacy and safety of acarbose in the treatment of type 2 diabetic patients in an observational setting. Keywords: type 2 diabetes, acarbose, Glucobay®, Glucor®, observational, noninterventional
format	article
author	Shihabi AR Moussa EM Sobierajska H Schmidt B
author_facet	Shihabi AR Moussa EM Sobierajska H Schmidt B
author_sort	Shihabi AR
title	An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco
title_short	An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco
title_full	An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco
title_fullStr	An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco
title_full_unstemmed	An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco
title_sort	observational study of acarbose treatment in patients with type 2 diabetes from the middle east and morocco
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/1549223104274878bc35fe84a2e17f12
work_keys_str_mv	AT shihabiar anobservationalstudyofacarbosetreatmentinpatientswithtype2diabetesfromthemiddleeastandmorocco AT moussaem anobservationalstudyofacarbosetreatmentinpatientswithtype2diabetesfromthemiddleeastandmorocco AT sobierajskah anobservationalstudyofacarbosetreatmentinpatientswithtype2diabetesfromthemiddleeastandmorocco AT schmidtb anobservationalstudyofacarbosetreatmentinpatientswithtype2diabetesfromthemiddleeastandmorocco AT shihabiar observationalstudyofacarbosetreatmentinpatientswithtype2diabetesfromthemiddleeastandmorocco AT moussaem observationalstudyofacarbosetreatmentinpatientswithtype2diabetesfromthemiddleeastandmorocco AT sobierajskah observationalstudyofacarbosetreatmentinpatientswithtype2diabetesfromthemiddleeastandmorocco AT schmidtb observationalstudyofacarbosetreatmentinpatientswithtype2diabetesfromthemiddleeastandmorocco
_version_	1718399617753677824

An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco

Ejemplares similares